how much allulose to trigger glp 1 Is a GLP-1 Agonist? Evidence and Key Differences D-Allulose Reduces Weight More Persistently

Understanding the differences between these delivery methods can help you make an informed decision

Diabetes pathogenic mechanisms and potential new therapies based upon a novel target called TXNIP

10.1016/j.neuropharm.2019.107813 173

the invention also relates to novel uses and methods of treatments using the aforementioned salts and/or compositions, in particular, with respect to the treatment of disturbances connected with either nitric oxide (NO) formation or impaired NO-system functions, in particular, hypertension, angina, impotence, circulatory and septic shock, stroke, inflammation, respiratory distress syndrome, adhesion and aggregation of platelets and leukocytes, endothelial dysfunction, gastrointestinal lesions, peristalsis disturbances, diabetes, pancreatitis, hypotension and Parkinson's disease